tolvaptan has been researched along with sorafenib in 2 studies
Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) |
---|---|---|---|---|---|
967 | 172 | 786 | 6,520 | 730 | 5,251 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Sas, KM | 1 |
1 review(s) available for tolvaptan and sorafenib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for tolvaptan and sorafenib
Article | Year |
---|---|
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Humans; Niacinamide; Phenylurea Compounds; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Tolvaptan | 2010 |